A COVID-19 vaccine that has been developed in China appears to be safe and effective. According to UPI, the vaccine successfully induced an immune response against the virus in a small trial. 95% of trial participants who received a high dose of the vaccine and 91% of those given a lower dose had immune responses. The study participants developed the immune response within 28 days of receiving the vaccination. The vaccine is based on a weakened human common cold virus, or adenovirus. The virus can infect human cells but is incapable of causing disease.
Be the first to comment